Global commercial distribution of temperature-sensitive pharmaceuticals can seem daunting for both established and emerging life sciences organizations. Cold chain packaging and shipping considerations change as a company moves from clinical to commercial operations, and new challenges related to COVID-19 still impact shipping. But that’s not all. The shift from chemically synthesized to more biologic drugs also requires greater temperature control.
As pharmaceutical companies embark on commercial distribution, it’s important to find a balance between too little attention to temperature control that can compromise a therapy and temperature control overkill that can lead to extraneous costs. Our most recent white paper helps provide insights on “right-sizing” warehousing, packaging, and shipping providers during the critical transition from clinical to commercial cold chain.
